Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of the business's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $35.44, for a total transaction of $70,880.00. Following the transaction, the vice president owned 128,443 shares of the company's stock, valued at approximately $4,552,019.92. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Mark Munch also recently made the following trade(s):
- On Thursday, January 15th, Mark Munch sold 2,000 shares of Bruker stock. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00.
- On Monday, January 12th, Mark Munch sold 7,000 shares of Bruker stock. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00.
Bruker Trading Down 2.9%
Shares of NASDAQ BRKR opened at $32.76 on Tuesday. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -218.40, a P/E/G ratio of 2.02 and a beta of 1.19. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The company's fifty day moving average is $43.13 and its 200-day moving average is $41.11.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker's quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts predict that Bruker Corporation will post 2.69 EPS for the current year.
Bruker Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, March 23rd. Bruker's dividend payout ratio is -133.33%.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. Guggenheim lifted their price objective on Bruker from $53.00 to $58.00 and gave the company a "buy" rating in a report on Monday, January 26th. The Goldman Sachs Group lowered their target price on Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research note on Friday, February 13th. TD Cowen cut their price target on shares of Bruker from $53.00 to $43.00 and set a "hold" rating on the stock in a research note on Friday, February 13th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Bruker in a report on Monday, December 29th. Finally, UBS Group reissued a "neutral" rating and set a $49.00 price objective on shares of Bruker in a research report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $50.38.
Get Our Latest Report on BRKR
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Orbis Allan Gray Ltd bought a new position in shares of Bruker during the second quarter worth about $192,735,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock valued at $111,488,000 after purchasing an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock worth $108,796,000 after purchasing an additional 1,756,460 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. acquired a new position in Bruker during the second quarter worth $62,032,000. 79.52% of the stock is owned by institutional investors and hedge funds.
Bruker Company Profile
(
Get Free Report)
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
